• Proteomics data sharing moved from validation to re-use. • New tools and services make data very easily accessible. • Metadata provision can still benefit from improvements. • Quality control metrics will soon be reported along with submitted data. • Data re-use will enable the advent of actual in silico proteomics.
No takes yet. Share an insight, caveat, or question.
Lennart Martens (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: